Smith & Nephew plc (SNN)
NYSE: SNN · Real-Time Price · USD
35.72
-0.21 (-0.58%)
Oct 9, 2025, 4:00 PM EDT - Market closed
Smith & Nephew Revenue
Smith & Nephew had revenue of $2.96B in the half year ending June 28, 2025, with 8.30% growth. This brings the company's revenue in the last twelve months to $5.94B, up 5.35% year-over-year. In the year 2024, Smith & Nephew had annual revenue of $5.81B with 4.70% growth.
Revenue (ttm)
$5.94B
Revenue Growth
+5.35%
P/S Ratio
2.57
Revenue / Employee
$329,125
Employees
18,060
Market Cap
15.30B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5.81B | 261.00M | 4.70% |
Dec 31, 2023 | 5.55B | 334.00M | 6.40% |
Dec 31, 2022 | 5.22B | 3.00M | 0.06% |
Dec 31, 2021 | 5.21B | 652.00M | 14.30% |
Dec 31, 2020 | 4.56B | -578.00M | -11.25% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SNN News
- 6 days ago - Smith+Nephew announce latest scientific data supporting new ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing for pressure injury prevention - GlobeNewsWire
- 8 days ago - Smith+Nephew launches CORIOGRAPH™ Pre-Op Planning and Modeling Services for total shoulder arthroplasty - GlobeNewsWire
- 4 weeks ago - Smith+Nephew unveils major clinical evidence and patient access updates for its REGENETEN™ Bioinductive Implant - GlobeNewsWire
- 5 weeks ago - Smith+Nephew extends Advanced Wound Bioactives portfolio with US launch of CENTRIO Platelet-Rich-Plasma System - GlobeNewsWire
- 2 months ago - Smith & Nephew: Doing Better And Still Offers Value - Seeking Alpha
- 2 months ago - Smith & Nephew plc (SNN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Top 2 Health Care Stocks You May Want To Dump In Q3 - Benzinga
- 3 months ago - Smith+Nephew expands market-leading fixation strength of Q-FIX™ All-Suture Anchor portfolio with new knotless option - GlobeNewsWire